Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
We performed a 1:1 matching of subjects treated with ALCAR 3 g/day with 45 not treated subjects and separately a 1:1 matching of subjects treated with ALCAR 1.5 g/day with 45 additional not treated subjects
These typically improve over time as your body adjusts: Nausea Vomiting Diarrhea Constipation Stomach pain Decreased appetite Serious but Rare Side Effects These occur in less than 1% of patients but require immediate medical attention: Pancreatitis (pancreas inflammation) Gallbladder problems Kidney problems Severe allergic reactions Changes in vision Low blood sugar Severe stomach problems Cancer, whether thyroid or pancreatic, does not appear to be a significant risk based on current human research
Long-term use often causes the body to resist insulin
Formula: C 230 H 341 N 57 O 68 Molecular Weight (MW): 4967.5 g/mol Dose: 12 mg Form: Lyophilised powder Purity: 98% (HPLC) Storage: 20C Documentation: COA + HPLC + Mass Spec Research Use Declaration This material is supplied exclusively for in-vitro and pre-clinical laboratory research purposes
The clinical presentation typically reflects an exaggeration of the medication's known pharmacological effects and adverse reaction profile
Biomarkers and Genetic Factors That Inform Dual-Therapy Suitability Biomarker profilesincluding eGFR, urine albumin-to-creatinine ratio, blood pressure, and lipidshelp define which patients gain most from dual therapy
